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Abstract
Background: In the aftermath of the largest Q fever outbreak in the world, diagnosing the potentially lethal
complication chronic Q fever remains challenging. PCR, Coxiella burnetii IgG phase I antibodies, CRP and 18F–FDG-
PET/CT scan are used for diagnosis and monitoring in clinical practice. We aimed to identify and test biomarkers in
order to improve discriminative power of the diagnostic tests and monitoring of chronic Q fever.
Methods: We performed a transcriptome analysis on C. burnetii stimulated PBMCs of 4 healthy controls and 6
chronic Q fever patients and identified genes that were most differentially expressed. The gene products were
determined using Luminex technology in whole blood samples stimulated with heat-killed C. burnetii and serum
samples from chronic Q fever patients and control subjects.
Results: Gene expression of the chemokines CXCL9, CXCL10, CXCL11 and CCL8 was strongly up-regulated in C. burnetii
stimulated PBMCs of chronic Q fever patients, in contrast to healthy controls. In whole blood cultures of chronic Q
fever patients, production of all four chemokines was increased upon C. burnetii stimulation, but also healthy controls
and past Q fever individuals showed increased production of CXCL9, CXCL10 and CCL8. However, CXCL9 and CXCL11
production was significantly higher for chronic Q fever patients compared to past Q fever individuals. In addition,
CXCL9 serum concentrations in chronic Q fever patients were higher than in past Q fever individuals.
Conclusion: CXCL9 protein, measured in serum or as C. burnetii stimulated production, is a promising biomarker for
the diagnosis of chronic Q fever.
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Background
Q fever is a zoonosis caused by the intracellular bacte-
rium Coxiella burnetii. Clinical presentation ranges from
asymptomatic acute infection to pneumonia or hepatitis.
One to 5 % of infected individuals develop chronic Q
fever, characterized by a persistent infection of heart-
valves, vascular aneurysms or prostheses. Chronic Q
fever patients may present years after their initial infec-
tion with C. burnetii. If left untreated, this condition has
a high mortality rate [1, 2]. To prevent irreparable dam-
age, early diagnosis of chronic Q fever is essential [3].
Today, diagnosis of chronic Q fever depends on Polyme-
rase Chain Reaction (PCR), measurement of anti-C. bur-
netii phase I IgG titers and imaging techniques [4–6].
Both laboratory techniques have drawbacks: PCR on
blood has a low sensitivity and the cut-off values of anti-
C. burnetii phase I to distinguish past from chronic
infection are still debated and are either not sensitive or
specific enough [7].
Even more challenging is the monitoring of chronic Q
fever during treatment. Currently, monitoring relies on
anti-C. burnetii phase I IgG titers, with a fourfold decrease
or a drop below 1:800 as criteria to stop treatment [2]. In
daily practice, titers hardly decrease and antibiotic therapy
is continued for many years [8]. In addition, many clini-
cians measure C-reactive protein levels to monitor disease
activity. Imaging by FDG-PET/CT scan is a promising tool
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in antimicrobial treatment decision making and its value
in chronic Q fever is under investigation [5, 6]. The limita-
tions of the current tests highlight the need for additional
biomarkers in diagnosis and monitoring.
To assess new candidate biomarkers for the diagnosis of
chronic Q fever and monitoring treatment, we performed
a transcriptome analysis on C. burnetii-stimulated periph-
eral mononuclear cells of chronic Q fever patients. We
validated the results in whole blood cultures and serum of
patients with Q fever and control subjects.
Methods
Subjects
Four groups were included: healthy controls, patients
with acute Q fever, patients with a history of cured acute
Q fever (past Q fever), and patients with chronic Q fever
(Fig. 1). Healthy controls (n = 28) were hospital
personnel and students without a history of Q fever.
Healthy controls with available serum samples (n = 9)
were Q fever seronegative. Specimens of anonymous
acute Q fever patients (n = 9), all PCR-positive for C.
burnetii at the time of blood-drawing, were collected
from left-over samples of patients identified between
2008 and 2009 in the Canisius Wilhelmina (CWZ) Hos-
pital. Left-over serum specimens of past Q fever patients
(n = 20), were also derived from the CWZ-hospital. An-
other 10 individuals with past Q fever, who provided
heparin-anticoagulated blood, were recruited in the Q
fever prevaccination screening program, described in de-
tail by Schoffelen et al. [9]. All samples were Coxiella bur-
netii phase II IgG positive and had low phase I IgG titers,
indicative for the absence of chronic Q fever. Chronic Q
fever patients (n = 65) visited the outpatient clinic of the
Radboud university medical center (n = 29) or the other
participating hospitals: Catharina Hospital Eindhoven
(n = 12), Elisabeth Hospital Tilburg (n = 9), CWZ-
Hospital (n = 6), Elkerliek Hospital Helmond (n = 5) and
Bernhoven Hospital Uden (n = 4). The chronic Q fever
group comprised 47 proven and 18 probable chronic Q
fever patients diagnosed according to the Dutch consen-
sus guideline on chronic Q fever [4]. Thirty-seven patients
presented with a vascular focus in an aneurysm or aortic
prosthesis, 19 had valvular defects, 6 had both a vascular
and valvular localization, and 3 patients were immuno-
comprised. All patients were on antibiotic treatment.
EDTA-anticoagulated blood for isolation of peripheral
blood mononuclear cells (PBMCs) was collected from
chronic Q fever patients and healthy controls. Heparin-
anticoagulated blood for stimulation experiments was
drawn from healthy controls, past Q fever and chronic
Q fever patients.
Peripheral blood mononuclear cells isolation and
transcriptome analysis
PBMCs were isolated from blood centrifuged with
Ficoll-Paque (GE Healthcare, Uppsala, Sweden) accor-
ding to standardized procedures [10]. Cells were taken
from the interphase layer, washed twice in Phosphate
Buffered Saline, and counted in a Coulter Counter Z
(Beckman Coulter, Fullerton, CA, USA). PBMCs were
then incubated in flat-bottom 24-wells plates in 1 mL
(107cells/mL) and stimulated with heat-killed C. burnetii
Nine Mile (NM) RSA493 phase I (kindly provided by dr
HJ Roest, CVI, Lelystad) in 107/mL at 37 °C for 8 h.
RNA was extracted with the RNeasy Mini kit (Qiagen,
Hilden, Germany). With the 2100 Bioanalyzer (Agilent
Technologies, Massy, France) and the RNA 6000 Nano
LabChip kit, the quality of the RNA was ensured. RNA
quantity was determined with the Nanodrop (Thermo
Scientific). Gene expression was analysed using Whole
Human Genome 4x44K microarrays (Agilent Technolo-
gies, Massy, France) and One-color Microarray based
Gene Expression Analysis kit, as previously described
[11]. Gene expression data was analysed with R and
Bioconductor software suite. Data was normalized with
quantile normalization after being preprocessed and
Fig. 1 Flow chart of subject groups
Total number of individuals in each group is depicted in the circles. The number of specimens per experiment of each group is described in the
squares.*, **: for chronic Q fever patients, 6 patients that were included in the transcriptome analysis and 22 patients of whom ex-vivo whole
blood stimulations were performed, also provided serum specimens
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quality checked (Agi4x44PreProcess library). With the
Limma library, differential gene expression was assessed.
Data was compliant with the Minimun Information
About a Microarray Experiment (MIAME) guidelines,
accessible with number GSE66476 at the National
Center for Biotechnology Information’s Gene Expression
Omnibus, (www.ncbi.nlm.nih.gov/geo/).
Whole blood stimulation experiments
Blood was drawn into 5 mL heparinized tubes. Subse-
quently 500 μL blood was incubated with either heat-
killed C. burnetii NM in an end concentration of 107/
mL or with culture medium (negative control) [12].
After 24 h of incubation at 37 °C and 5% CO2, the
supernatants were harvested and stored at -80 °C.
Measurement of proteins and anti-C. burnetii serology
Interferon-γ (IFN-γ) production in stimulated whole
blood supernatants was measured with commercially
available enzyme-linked immunosorbent assay (ELISA)
(Sanquin, Amsterdam, Netherlands) according to the
manufacturer’s instructions. The CXCR3-chemokines
and CCL8 were determined in stimulated whole blood
supernatants and serum using Luminex technology (Bio-
Rad, CA, USA). CRP from serum was measured with
immunoturbidimetry (Architect, Siemens; and Cobas
6000, Roche) and anti-C. burnetii antibodies were deter-
mined in serum by indirect immunofluorescence meas-
uring IgM and IgG against C. burnetii NM phase I and
II a commercially available immunofluorescence assay
(IFA, Focus Diagnostics Inc., Cypress, CA, USA).
Statistical analysis
Data was analysed using GraphPad Prism and SPSS soft-
ware programs and presented with medians and inter-
quartile range (IQR) or minimum to maximum range
(range) as cytokine and chemokine data is considered
non-parametric. Differences between groups were
assessed with the Kruskal Wallis test and completed with
Dunn multiple comparison tests, a p-value of <0.05 was
considered significant. Spearman’s rho was used for deter-
mining correlation. To assess the accuracy the proposed
biomarkers, a receiver operator characteristic (ROC) curve
was constructed and the area under the curve (AUC) was
calculated. Whether there was a correlation of the bio-
markers with time after start of treatment was determined
per patient by a non-linear best fit regression model.
Results
Gene expression profiles reveal up-regulation of IFN-γ
inducible genes in chronic Q fever
Transcriptional profiles of PBMCs of 4 healthy controls
were compared to the PBMCs of 6 chronic Q fever pa-
tients that were in-vitro stimulated with heat-killed C.
burnetii. To look for candidate biomarkers, genes were
selected that were most differentially expressed in both
groups. Four genes encoding for chemokines ended at
the top of the list: CXCL9 also named Monokine In-
duced by IFN-γ (MIG), CXCL10 (IFN-γ Inducible
Protein-10 (IP-10)), CXCL11 (IFN-γ T-cell Attractant
Chemokine (I-TAC)), and CCL8 (Monocyte Chemotactic
Protein (MCP-2)) (Table 1). CXCL9, CXCL10 and
CXCL11 are ligands for CXCR3 and are therefore named
CXCR3-chemokines.
Whole blood cultures show that C. burnetii induces
production of CXCR3-chemokines
To validate the results from the gene expression analysis
and to assess the suitability of measurement of the gene-
products, the production of these proteins in C. burnetii
stimulated whole blood was determined (Fig. 2). These
experiments were performed with blood from 15 healthy
volunteers, 20 past Q fever and 36 chronic Q fever pa-
tients, who were diagnosed (median) 20 months before
blood sampling.
Healthy controls showed significant C. burnetii-in-
duced production of CXCL9, CXCL10 and CCL8, but
no production of CXCL11. The same pattern was
seen in past Q fever individuals. Chronic Q fever
patients showed increased production of all four che-
mokines (CXCL9, CXCL10, CXCL11 and CCL8).
CXCL9 production was significantly higher in chronic
Q fever patients (median 15.1 ng/mL, IQR 8.5–26.5)
than in healthy controls (median 3.6 ng/mL, IQR
1.7–8.2, p < 0.05) and past Q fever patients (median
3.8 ng/mL, IQR 2.8–5.3, p < 0.05). CXCL11 produc-
tion in chronic Q fever patients (median 146 pg/mL,
IQR 83–230) was higher than in past Q fever patients
(median 66 pg/mL, IQR 43–183, p < 0.05).
A Receiver-operator-curve (ROC) analysis was per-
formed for CXCL9 and CXCL11 to distinguish between
chronic Q fever patients and past Q fever patients. The
test accuracy, denoted by the area under the curve
Table 1 RNA expression in C. burnetii stimulated PBMCs
C. burnetii stimulated PBMCs
Healthy controls Chronic Q
fever patients
Ratio patient/
healthy control
CXCL11 / I-TAC 0.10 15.5 155
CXCL9 / MIG 0.45 62.5 139
CCL8 / MCP-2 0.50 46.3 93
CXCL10 / IP-10 0.20 16.5 83
RNA expression in C. burnetii stimulated PBMCs of healthy controls (n = 4) and
chronic Q fever patients (n = 6). Median fold change from unstimulated
condition is indicated. Abbreviations: PBMCs peripheral blood mononuclear
cells, I-TAC IFN-γ T-cell Attractant Chemokine, MIG Monokine Induced by
IFN- γ; MCP Monocyte Chemotactic Protein, IP-10 IFN- γ Inducible Protein-10
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(AUC), was 85% (CI: 75–95%) for CXCL9 and 78% (CI:
66–90%) for CXCL11.
Further analysis of the CXCL11 production in chronic
Q fever patients showed that production in samples taken
within 3 months after diagnosis (n = 5) was significantly
higher than in samples taken later in the course of the dis-
ease (n = 20, p < 0.05), but not for the other chemokines.
Because the identified chemokines are all induced by
IFN-γ, their correlation with C. burnetii-specific IFN-γ
production in the whole blood culture supernatants was
assessed. Generally, correlation was moderate (Additional
file 1: Fig. S1). The correlation coefficient (Spearman) was
0.54 for CXCL9 (p < 0.001), 0.70 for CXCL10 (p < 0.001),
0.50 for CXCL11 (p < 0.001) and 0.53 for CCL8
(p < 0.001).
Circulating CXCL9 serum levels are high in chronic Q
fever patients
We measured circulating chemokines in serum of 9 healthy
controls, 10 past Q fever individuals, 9 acute Q fever and
51 chronic Q fever patients. Chronic Q fever patients were
treated for a median of 13 months (range 0–46).
Chronic Q fever patients exhibited significantly higher
serum concentrations of CXCL9 (median 899 pg/mL,
range 92–12,734), CXCL10 (median 311 pg/mL, range
16–1497) and CXCL11 (median 21 pg/mL, 4–106) com-
pared to healthy controls (CXCL9 230 pg/mL, 164–557,
p < 0.001, CXCL10 151 pg/mL, 73–264, p < 0.05, CXCL11
10 pg/mL, 5–15, p < 0.01, Fig. 3). Chronic Q fever patients
showed higher CXCL9 serum concentrations than past Q
fever individuals (median 537 pg/mL, 82–927). Chronic Q
A
C D
B
Fig. 2 Chemokine production in whole blood cultures. a–d Chemokine production in whole blood cultures of healthy controls (n = 15), past Q
fever infected patients (n = 20) and chronic Q fever patients (n = 36) after 24 h stimulation with C. burnetii 107/mL compared to culture medium
RPMI. Medians with IQR are indicated. Kruskal Wallis with Dunn’s multiple comparisons test was performed. *: p < 0.05, **: p < 0.01, ***: P < 0.001,
ns: not significant. Abbreviations: RPMI, Roswell Park Memorial Institute Medium; Cb NM, C. burnetii Nine Mile, IQR, Interquartile range
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fever patients did not have higher levels of CXCL10 or
CXCL11 than past Q fever individuals (median 204 pg/
mL,10–464 and median 18 pg/mL, 6–72). Concentrations
of CCL8 were low in all groups and did not differ between
groups. As compared to chronic Q fever patients, acute Q
fever patients had higher CXCL10 serum concentrations
(median 1204 pg/mL, 180–1439, p < 0.01). The other che-
mokines did not differ between chronic Q fever and acute
Q fever patients.
ROC analysis of the CXCL9 serum concentrations
of chronic Q fever compared to past Q fever
individuals resulted in a test accuracy of 79% (de-
noted by the AUC, CI 67–92%, Fig. 3e). The sensi-
tivity was 73% and specificity 80%, when a cut-off
(580 pg/mL) was chosen that yielded both a high
sensitivity and specificity.
Clinical parameters of the patients at diagnosis, such
as PCR positivity in blood or tissue, and anti C. burnetii
phase I IgG titers were compared to the performance of
CXCL9 serum concentration at the 580 pg/mL cut-off
value (Table 2 and a detailed description in Additional
file 2: Table S1).
A B
C
E
D
Fig. 3 Circulating chemokines in serum. Circulating levels of chemokines, medians with interquartile range are indicated. Panel (a–d) display
CXCL9, CXLC10, CXCL11 and CCL8 serum levels respectively, in healthy controls (n = 9), past Q fever individuals (n = 10), acute Q fever (n = 9),
and chronic Q fever (n = 51). Kruskal Wallis with Dunn’s multiple comparisons test was performed. Panel (e) represents the Receiver Operating
Characteristic (ROC curve) of CXCL9 concentration in serum in chronic Q fever patients or past Q fever individuals. *: p < 0.05, **: p < 0.01, ***:
P < 0.001, ns: not significant
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Further analysis of the CXCR3-chemokine serum con-
centrations revealed that samples taken within one
month after diagnosis of chronic Q fever (n = 9) were
significantly higher for CXCL9 (p < 0.05) and CXCL10
(p < 0.05) than samples taken more than 1 month after
diagnosis (n = 41).
Circulating serum concentrations of CXCR3-chemokines
during follow-up show no correlation with treatment
duration
As circulating CXCR3-ligands were high in chronic Q
fever patients, we investigated whether they would de-
crease during the course of treatment and could be used
as marker for monitoring the effect of treatment. To this
end, we analysed serum samples taken at regular inter-
vals of 28 chronic Q fever patients during their visits to
the outpatient clinic. In total, 137 serum samples were
available (median 5 samples per patient (range 2–7),
between 0 to 62 months after start of treatment). In a
nonlinear best fit regression model, the slopes of the
regression lines per patient were calculated and the me-
dian slope was generated for CXCL9 (−5.0, range − 1959
to 23), CXCL10 (−0.8, range − 125,550 to 22), CXCL11
(−0.2, −14 to 1.6) and CCL8 (−0, −19 to 35) indicating
that there was no relation between chemokine levels and
treatment duration per patient (Fig. 4). Similar results
were obtained when time after last positive PCR in blood
was taken into account.
CXCR3-chemokines are weakly correlated to IgG phase I
and C-reactive protein
In 135 serum samples from 40 chronic Q fever patients
the corresponding anti-C. burnetii IgG phase I titers
were known. There was a weak correlation between IgG
phase I titers and CXCL9 (Spearman r = 0.24, p < 0.01)
but no correlation with the other chemokines.
The acute phase protein C-reactive protein is elevated
in various inflammatory conditions including Q fever
and is determined during treatment to monitor disease
activity. Seventy-six CRP values were available from 27
patients. Fifty-eight samples were below the detection
limit of the test (5 mg/L), whereas only 5 CRP values
were above 50 mg/L. We assessed the correlation of the
CRP values to the concurrent chemokine serum concen-
trations and found a weak correlation with CXCL9
(r = 0.25, p < 0.05) and CXCL11 (r = 0.47, p < 0.001),
but not with the other chemokines.
Discussion
In the present study, we searched for new biomarkers
for diagnosis and monitoring of chronic Q fever. With a
transcriptome analysis, we found 4 highly up-regulated
chemokine genes, induced by IFN-γ, in response to heat-
killed C. burnetii. Subsequent whole blood stimulation
experiments and the measurement of serum concentra-
tions showed that C. burnetii-stimulated CXCL9 and
CXCL11 production was higher in chronic Q fever pa-
tients compared to past Q fever individuals, and that
serum concentrations of CXCL9 were higher in chronic
Q fever patients compared to past Q fever individuals.
This suggests that particularly CXCL9 could aid in the
diagnosis of chronic Q fever.
CXCL chemokines are small chemotactic proteins, char-
acterized by the presence of four cysteines with a variable
amino acid ‘X’ dividing them [13]. As suggested by their
alternative names, the four mentioned chemokines share
the same inducer IFN-γ. In addition, CXCL10, CXCL11
and CCL8 can also be induced by type I interferons and
by TNF-α, whereas this is not the case for CXCL9. These
chemokines can be expressed by a variety of cells such as
PBMCs, macrophages, endothelial cells and fibroblasts
[13]. CXCL9, CXCL10 and CXCL11 are a ligand of the
same CXCR3-receptor located on NK-cells, effector T-
cells, dendritic cells and many non-immune cell types.
Even though these 3 chemokines have similar properties,
their affinity for CXCR3 varies and their expression
Table 2 Comparison of diagnostic characteristics and CXCL9
serum concentration
Diagnostic parameters Proven chronic
Q fever (n = 38),
(%)
Probable chronic
Q fever (n = 13),
(%)
IgG phase I > 1:1024 at diagnosis 32/32 (100%) 11/13 (85%)a
PCR blood/tissue positive 26/31 (81%) -
CRP >10 mg/L at diagnosis 5/14 (36%) 1/2 (50%)
Serum CXCL9 > 580 pg/mL 31/38 (82%) 6/13 (46%)
aTwo patients had IgG phase I levels of 1: 512 and were diagnosed based on
FDG-positive lesions on the ventral side of the heart with a mechanical aortic
valve and a FDG-avid lesion in the ascending aorta, near the pre-existing
aneurysm of the thoracic aorta
Fig. 4 Non linear regression lines of CXCL9 serum concentrations per
patient. Non-linear regression lines of CXCL9 serum concentrations per
chronic Q fever patient in months from diagnosis, a best fit model
was adapted
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depends on time and stimulus, suggesting critical differ-
ences in production and function [14, 15]. CXCL9 and
CXLC10 are degraded by matrix metalloproteinase-8
(MMP-8) and MMP-9 respectively [16], therefore, differ-
ences in concentration of active MMP-8 or MMP-9 may
influence the levels and functionality of CXCL9 and
CXCL10. With respect to the immune response against
intracellular bacteria such as C. burnetii, it is of interest
that CXCR3-chemokines have also been examined as can-
didate markers for the differentiation between active and
latent tuberculosis [17], as a possible alternative for IFN-γ
release assay (IGRA) in latent tuberculosis [18] and for
follow-up of tuberculosis treatment [19].
As we published recently, C. burnetii antigen-specific
CXCL10 production was high during the acute stage of
C. burnetii-infected BALB/c mice [20]. In line with this,
we report high CXCL10 serum concentrations in human
acute Q fever patients during the early stage of their dis-
ease. Although it is tempting to speculate that CXCL10
may be an early marker for acute Q fever, CXCL10 is
likely an inflammation marker rather than being specific
for acute Q fever [21, 22].
Previously, we published that cytokine production
(TNF-α, IL-1β, IL-1Ra, IL-4, IL-5, IL-6, IL-10, IL-12p70,
IL-23, IL-18) in C. burnetii-stimulated diluted blood did
not distinguish seropositive controls from chronic Q
fever patients, whereas the ratio of IFN-γ/IL-2 produc-
tion appeared to accurately identify chronic Q fever
patients with 79% sensitivity and 96% specificity [23].
Despite its usefulness, this assay is rather laborious, be-
cause it demands stimulation and incubation of whole
blood cultures. Reviewing the results from the current
study we can argue that simple measurement of CXCL9
serum concentration may also be of help in distinguish-
ing chronic Q fever from past infection, although its
specificity and sensitivity is somewhat lower than the
IFN-γ/IL-2 production assay.
It is reasonable to believe that the circulating CXCR3 li-
gands are not exclusively raised in chronic Q fever. Circu-
lating CXCL9 and CXCL10 concentrations are also
elevated in patients with heart failure, but to a lesser extent
than what we observed in chronic Q fever patients [24, 25].
More importantly, we have not addressed the specificity of
CXCL9 in relation to other pathogens that elicit a T-helper
1 cell response, such as mycobacterium tuberculosis and
others. It is likely that these infections will at least tempor-
arily induce elevated serum concentrations of the CXCR3
ligands. These caveats need to be considered when measur-
ing CXCL9 serum concentrations in patients suspected of a
chronic infection. C. burnetii stimulated CXCL9 production
may be more specific than serum concentration, although
this was not tested in the current study. It has to be noted
that conclusions on CXCR3 biomarkers should not be
based on the transcriptome analysis alone, but need to be
considered in light of the validation experiments. Addition-
ally, the small sample size of the transcriptome analysis
deems cautious interpretation.
Another limitation is the variable time after diagnosis
of chronic Q fever at which the first sample was taken, 9
serum samples were taken within one month after diag-
nosis. This may have led to an underestimation of the
discriminative power in the early phase of the disease.
Adding to this effect is the unknown Q fever status of
part of the healthy controls who provided samples for
whole blood stimulation. In the Netherlands, within the
center of the endemic area, the prevalence of C. burnetii
antibodies is about 5% [26].
We also focused on the capacity of IFN-γ induced
CXCR3-chemokines to monitor disease activity in chronic
Q fever. Overall, we found that serum samples taken
shortly after diagnosis displayed higher CXCL9 and
CXCL10 concentrations compared to samples drawn after
long-term antibiotic treatment. Assuming that antibiotics
are effective in lowering disease activity, this may indicate
that CXCL9 and CXCL10 levels are related to disease ac-
tivity. However, we found no correlation between chemo-
kine levels and duration of antibiotic treatment. Of note,
all chronic Q fever patients included in the present study
were still under treatment and according to the traditional
markers of disease activity, were considered to have active
disease. The absence of cured patients in our cohort lim-
ited our ability to detect any direct correlation between
chemokine levels and disease activity.
Traditional markers for diagnosing and monitoring
chronic Q fever are anti-phase I IgG titers, reflecting a
specific B-cell derived humoral immune response and CRP,
a product of an aspecific IL-6 mediated inflammatory
response, used to detect complications and concomitant
infections. Arguably, these markers might not accurately
reflect disease activity, since the protective immune re-
sponse against C. burnetii is predominantly an IFN-γ medi-
ated T-helper 1 response. Anti-phase I IgG antibodies play
a relatively small role in the adequate immune response to
C. burnetii [27, 28].
Reportedly, CRP is high in the acute stage of acute Q
fever [29, 30]. However, as we have shown, CRP is un-
detectable in most samples of chronic Q fever patients
and therefore not a suitable marker for disease remission
in chronic Q fever. Thus, the weak correlation of CRP and
CXCL9 found in our study is expected. Given the small
role of the humoral immune response in intracellular in-
fections, it may not be surprising that serum CXCL9 is
only weakly correlated with anti-phase I IgG titers.
Conclusion
In conclusion, CXCL9, as a marker of cell-mediated im-
munity, is a promising candidate to improve the diag-
nostic accuracy of chronic Q fever.
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Additional file 1: Fig. S1. Correlation of chemokine production with
interferon-γ production. Panel A–D: Scatter plots of chemokine production
and corresponding interferon-γ production after ex-vivo whole blood
stimulation with heat killed C. burnetii NM 107/mL. (EPS 134 kb)
Additional file 2: Table S1. Patient Characteristics. Diagnostic
characteristics of the chronic Q fever patients cohort. (PDF 37 kb)
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